COMMUNIQUÉS West-GlobeNewswire

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
10/02/2026
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, [...]
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
10/02/2026
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for [...]
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
10/02/2026
Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT ™ ) with its innovative RadioGel ® technology, today provided an [...]
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
10/02/2026
CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s [...]
Survey Reveals the Hidden Mental & Social Burden of Managing Celiac Disease
10/02/2026
More than half of people with celiac say they feel isolated or excluded; a majority admit they avoid restaurants and family gatherings just to prevent accidental gluten exposure BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE [...]
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
10/02/2026
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0. [...]
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
10/02/2026
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United States SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a [...]
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephology (JASN)
10/02/2026
MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 ST. LOUIS, Feb [...]
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
10/02/2026
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV [...]
RenovoRx Establishes RenovoCath® Medical Advisory Board
10/02/2026
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical Need MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- [...]
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
10/02/2026
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) [...]
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
10/02/2026
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil) PARAMUS, NJ, Feb. 10, 2026 (GLOBE [...]
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
10/02/2026
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placebo Prospective [...]
Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era
10/02/2026
The new partnership combines Weight Watchers’ scientifically-backed medical and behavioral expertise with PVOLVE’s clinically-studied method to support members at every age and stage of life NEW YORK, Feb. 10, 2026 ( [...]
TerrAscend to Host Fourth Quarter and Full Year 2025 Earnings Conference Call
10/02/2026
TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
OraSure to Launch OraQuick™ HIV Self-Test in Canada
10/02/2026
BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick [...]
Fangzhou’s MaaS Platform Recognized as Industry Leader at Guangdong Digital Economy Conference
10/02/2026
GUANGZHOU, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, received prominent industry recognition at [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
10/02/2026
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10/02/2026
Financing led by Investissement Qu é bec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients MONTREAL and [...]

Pages